Journal Article
. 2012 Jun;134(2).
doi: 10.1007/s10549-012-2112-7.

TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer

Joseph A Sparano 1 Lori J Goldstein  Nancy E Davidson  George W Sledge  Robert Gray  
  • PMID: 22706628
  •     17 References
  •     5 citations


The purpose of this study is to evaluate the relationship between TOP2A RNA expression and recurrence in patients with operable estrogen receptor (ER)-positive breast cancer. We evaluated TOP2A expression in a pooled analysis of four independent datasets with gene expression data including 752 patients with early stage, ER-positive, HER2-negative breast cancer, most of whom received either no adjuvant therapy or only endocrine therapy without chemotherapy. We also used an algorithm to simulate the Oncotype DX Recurrence Score (simRS) and the proliferation component of the Recurrence Score (simPS). Results are expressed as the hazard ratio (HR) for estimates of the effect of a 1SD increase in the value of the log gene expression (x + 1SD vs. x) as a continuous function. TOP2A expression was significantly associated with recurrence (HR 1.56, p < 0.0001), and after adjustment for simRS (HR 1.26, p = 0.003). TOP2A correlated somewhat with simRS (0.45), but more strongly with simPS (0.69). For those with an intermediate simRS, high TOP2A expression (above the median) was associated with significantly higher relapse rates at 5 years (HR 1.82, p = 0.007). TOP2A expression provides prognostic information in patients with ER-positive, HER2-negative breast cancer, a population known to have low incidence of TOP2A gene alterations. These findings confirm prior reports indicating that TOP2A expression provides prognostic information in ER-positive breast cancer. TOP2A expression may also be useful for identifying those with an intermediate RS who are more likely to relapse, although additional validation in datasets including measured rather than simulated RS will be required.

Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series.
Christine Desmedt, Fanny Piette, +18 authors, TRANSBIG Consortium.
Clin Cancer Res, 2007 Jun 05; 13(11). PMID: 17545524
Highly Cited.
DNA topoisomerase poisons as antitumor drugs.
L F Liu.
Annu Rev Biochem, 1989 Jan 01; 58. PMID: 2549853
Highly Cited. Review.
Topoisomerase II-alpha expression in different cell cycle phases in fresh human breast carcinomas.
Kenneth Villman, Elisabeth Ståhl, +2 authors, Mats G Karlsson.
Mod Pathol, 2002 May 16; 15(5). PMID: 12011253
Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection.
Shelly S Lo, Patricia B Mumby, +8 authors, Kathy S Albain.
J Clin Oncol, 2010 Jan 13; 28(10). PMID: 20065191
Highly Cited.
Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer.
A Rody, T Karn, +7 authors, M Kaufmann.
Breast Cancer Res Treat, 2008 Mar 15; 113(3). PMID: 18340528
Development of the 21-gene assay and its application in clinical practice and clinical trials.
Joseph A Sparano, Soonmyung Paik.
J Clin Oncol, 2008 Feb 09; 26(5). PMID: 18258979
Highly Cited. Review.
TAILORx: trial assigning individualized options for treatment (Rx).
Joseph A Sparano.
Clin Breast Cancer, 2006 Nov 10; 7(4). PMID: 17092406
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.
Yixin Wang, Jan G M Klijn, +11 authors, John A Foekens.
Lancet, 2005 Feb 22; 365(9460). PMID: 15721472
Highly Cited.
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade.
Sherene Loi, Benjamin Haibe-Kains, +14 authors, Christos Sotiriou.
J Clin Oncol, 2007 Apr 03; 25(10). PMID: 17401012
Highly Cited.
Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer.
Joseph A Sparano, Lori J Goldstein, +12 authors, Robert Gray.
Clin Cancer Res, 2009 Dec 10; 15(24). PMID: 19996222    Free PMC article.
ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction.
Jan C Brase, Marcus Schmidt, +7 authors, Mathias C Gehrmann.
Clin Cancer Res, 2010 Apr 08; 16(8). PMID: 20371687
Physician survey of the effect of the 21-gene recurrence score assay results on treatment recommendations for patients with lymph node-positive, estrogen receptor-positive breast cancer.
Ruth Oratz, Benjamin Kim, +4 authors, Michael Broder.
J Oncol Pract, 2011 Jul 07; 7(2). PMID: 21731516    Free PMC article.
A gene-expression signature as a predictor of survival in breast cancer.
Marc J van de Vijver, Yudong D He, +18 authors, René Bernards.
N Engl J Med, 2002 Dec 20; 347(25). PMID: 12490681
Highly Cited.
Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen.
Sherene Loi, Benjamin Haibe-Kains, +16 authors, Christos Sotiriou.
BMC Genomics, 2008 May 24; 9. PMID: 18498629    Free PMC article.
Highly Cited.
Re: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.
Catherine Oakman, Erica Moretti, +2 authors, Angelo Di Leo.
J Natl Cancer Inst, 2009 Nov 07; 101(24). PMID: 19893008
DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes.
Libero Santarpia, Takayuki Iwamoto, +9 authors, Giampaolo Bianchini.
Oncologist, 2013 Sep 28; 18(10). PMID: 24072219    Free PMC article.
TOP2A gene copy number change in breast cancer.
M J Engstrøm, B Ytterhus, +2 authors, A M Bofin.
J Clin Pathol, 2014 Jan 10; 67(5). PMID: 24403186    Free PMC article.
Prognostic gene expression assays in breast cancer: are two better than one?
Joseph A Sparano.
NPJ Breast Cancer, 2018 May 31; 4. PMID: 29845110    Free PMC article.
Overexpression of topoisomerase II alpha protein is a factor for poor prognosis in patients with luminal B breast cancer.
Hideo Shigematsu, Shinji Ozaki, +7 authors, Kiyomi Taniyama.
Oncotarget, 2018 Jun 22; 9(42). PMID: 29928479    Free PMC article.
MGMT inhibition in ER positive breast cancer leads to CDC2, TOP2A, AURKB, CDC20, KIF20A, Cyclin A2, Cyclin B2, Cyclin D1, ERα and Survivin inhibition and enhances response to temozolomide.
George C Bobustuc, Amin B Kassam, +7 authors, Santhi D Konduri.
Oncotarget, 2018 Jul 25; 9(51). PMID: 30038716    Free PMC article.